Literature DB >> 2809499

Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis.

L Grinsted1, A Heltberg, C Hagen, H Djursing.   

Abstract

Dysfunctions within the hypothalamic-pituitary-gonadal axis occur frequently among women with multiple sclerosis (MS) and may induce menstrual disturbances and subsequent infertility. We have measured serum concentrations of prolactin. gonadotropins and sex hormone binding globulin (SHBG) as well as free and bound oestrogen and androgen levels in 14 women of fertile age with MS. These women all displayed regular cycles without having experienced fertility problems. As controls 14 normal women with regular periods and ideal body weight of 91% (range 80-101) were included. Serum from both groups was sampled during the early follicular phase. The MS-patients had significantly (P less than 0.05) higher concentrations of prolactin, LH, FSH, total and free testosterone (P less than 0.01) and a significantly lower serum concentration of oestrone sulphate (P less than 0.01). The abnormal hormone concentrations were not related to clinical status of the disease. We propose that the increased androgen levels are of ovarian origin as adrenal androgens were normal. The reason for the slight increase of prolactin and the marked increase of gonadotropins in women with MS is speculative. As oestradiol levels, however, were within normal range, we assume that a peripheral resistance to gonadotropins combined with an abnormal central regulation causes the increased pituitary secretion.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2809499     DOI: 10.1111/j.1365-2796.1989.tb01387.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  14 in total

Review 1.  Caring for Women with Multiple Sclerosis Across the Lifespan.

Authors:  Kelsey Rankin; Riley Bove
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

Review 2.  Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs.

Authors:  Maria Pia Amato; Emilio Portaccio
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

3.  Assessment of ovarian reserve and Doppler characteristics in patients with multiple sclerosis using immunomodulating drugs.

Authors:  Aylin Pelin Cil; Alev Leventoğlu; Murat Sönmezer; Rabia Soylukoç; Kutluk Oktay
Journal:  J Turk Ger Gynecol Assoc       Date:  2009-12-01

Review 4.  Impact of sex hormones on immune function and multiple sclerosis development.

Authors:  María C Ysrraelit; Jorge Correale
Journal:  Immunology       Date:  2018-10-11       Impact factor: 7.397

5.  Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report.

Authors:  A Aserlind; A DeCherney
Journal:  Glob Reprod Health       Date:  2020

6.  Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy.

Authors:  Nadja Borisow; Andrea Döring; Caspar F Pfueller; Friedemann Paul; Jan Dörr; Kerstin Hellwig
Journal:  EPMA J       Date:  2012-06-22       Impact factor: 6.543

7.  Evaluating sex hormone levels in reproductive age women with multiple sclerosis and their relationship with disease severity.

Authors:  Azam Foroughipour; Vajihe Norbakhsh; Sara Hosseinpour Najafabadi; Rokhsareh Meamar
Journal:  J Res Med Sci       Date:  2012-09       Impact factor: 1.852

Review 8.  Gender and sex hormones in multiple sclerosis pathology and therapy.

Authors:  Arnaud Nicot
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

9.  Is Fertility Affected in Women of Childbearing Age with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?

Authors:  Niyousha Sadeghpour; Omid Mirmosayyeb; Geir Bjørklund; Vahid Shaygannejad
Journal:  J Mol Neurosci       Date:  2020-08-01       Impact factor: 3.444

Review 10.  Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies.

Authors:  Isabella Laura Simone; Carla Tortorella; Alma Ghirelli
Journal:  Front Neurol       Date:  2021-07-01       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.